Please login to the form below

Not currently logged in
Email:
Password:

CRPC

This page shows the latest CRPC news and features for those working in and with pharma, biotech and healthcare.

J&J puts pressure on rivals with new Erleada okay in prostate cancer

J&J puts pressure on rivals with new Erleada okay in prostate cancer

Meanwhile, Zytiga – which is only approved for metastatic CRPC – pulled in $3.5bn last year, but the start of generic competition in late 2018 was evident in a 21% slump in

Latest news

More from news
Approximately 1 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    In patients with non-metastatic CRPC, there is a high unmet need to delay development of metastases and the progression to advanced prostate cancer. ... for approval in the US and EU for non-metastatic CRPC on the strength of MFS data from the PROSPER

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics